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Patients with primary refractory or relapsed-acute myeloid
leukemia (RR-AML), particularly older adults, have dismal
outcomes and limited therapy options [1]. Given the tol-
erability of hypomethylating agents (HMAs) and ability to
administer therapy on an outpatient basis, as well as limi-
tations to clinical trial availability and eligibility, some
patients with RR-AML are treated with the HMAs azaciti-
dine or decitabine [1,2]. Using a large, international, mul-
ticenter database of RR-AML patients treated with HMAs,
we have previously reported that 16% of patients
achieved a complete response (CR) or CR with incomplete
count recovery (CRi) with HMAs and experienced a
median overall survival (OS) of 21 months [3].
However, similar to the situation in the frontline ther-
apy setting, responses occur in a minority of patients and
identification of clinical or laboratory predictors, which
might help select patients who are likely to benefit from
HMA therapy is ideal [4]. The Medical Research Council
(MRC) and Leukemia Research Foundation (LRF) devel-
oped a score, recently published in Leukemia and
Lymphoma [5], which predicts that older AML patients
benefit from azacitidine as frontline therapy. However, lit-
tle is known how this risk assessment tool performs in
the refractory and relapsed setting, or among patients
treated with decitabine. Here we analyzed the perform-
ance of the MRC/LRF tool in the prediction of OS in RR-
AML patients after therapy with HMAs using our large,
international, multicenter database.
Our database included retrospectively collected data
from 655 patients with RR-AML who were treated with
HMAs in the 2006 to 2016 period from seven centers in
the United States and five centers in Europe.
Kaplan–Meier methods estimated OS and one-year OS
from initiation of HMAs to death or end of follow-up.
Patients who underwent allogeneic hematopoietic cell
transplantation (alloHCT) were censored at the time of
transplantation. Survival analysis was stratified according
to the MRC/LRF risk categories of good, standard, and
poor risk. Covariates for the MRC/LRF score include age,
Eastern Cooperative Oncology Group Performance Status
(ECOG PS), white blood cell count (WBC) at HMA initi-
ation, AML type (de novo or secondary) and cytogenetic
risk category according to MRC (favorable, intermediate,
adverse). Missing data were imputed using the
Multivariate Imputation by Chained Equation approach
[6]. There were 10 imputed datasets generated from a
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model with 68 variables using random forest imputation
with 500 trees for missing continuous and unordered cat-
egorical data, and polytomous logistic regression for
missing ordered categorical data. These methods
restricted the imputed data to take plausible values
found within the original data.
Of the 655 patients, 365 patients (56%) had relapsed
AML and 290 (44%) had primary refractory AML (Table 1).
Median age at start of HMA therapy was 65 years (range
[R], 16–92) and the median ECOG PS was 1. Median WBC
at HMA therapy was 3.2 109/L (R, 0.1–110.5 109/L) and
22.4%, 4.4%, and 0.2% of patients had a WBC of
>10 109/L, > 50 109/L, and >100 109/L, respectively.
Although 458 patients (70%) had de novo AML, 192
patients had secondary AML (30%). Only 1.8% of patients
demonstrated a good risk karyotype based on MRC cyto-
genetic risk, whereas 58.2% and 40% of patients had an
intermediate or poor risk karyotype.
Applying the MRC/LRF score, 20.9% of patients were
categorized as a good risk, and hence more likely to
benefit from therapy HMA, whereas 24.7% and 54.3% of
patients were categorized as standard and poor risk,
respectively. While 360 patients (56.8%) were treated with
azacitidine, 274 patients received decitabine (43.2%). The
median OS for the entire group of patients was 6.7
months (95% CI, 6.1–7.3). As expected, the median OS for
responding patients was longer than that of nonrespond-
ing patients within each risk category of the MRC/LRF
score. Median OS for patients treated with either azaciti-
dine or decitabine (Figure 1) was 6.8 months for patients
with either good or standard risk and 5.8 months for
patients with poor risk based on MRC/LRF (hazard ratio
[HR] of death for the poor risk group compared with the
good/standard risk group was 1.3, p¼ .090). The one-year
OS probability was 29.2% (95% CI 17.8–41.2%) versus
19.6% (95% CI 9.6–32.0%) for good/standard risk and
poor risk patients, respectively (p¼ .13) (Figure 1). For the
subgroup of patients treated with azacitidine, median OS
for patients with good/standard versus poor risk was 8.5
months compared with 6.2 months (HR ¼1.2, p¼ .23)
(Figure 2(A)). The one-year OS probability was 32.7%
(95% CI 24.2–41.4%) versus 24.2% (95% CI 18.1–30.7%)
for poor versus good/standard (p¼ .059). For patients
treated with decitabine, the difference in OS based on
MRC/LRF was less pronounced with good/standard risk
compared with poor risk patients experiencing a median
OS of 5.6 and 5.3 months, respectively (HR ¼1.2, p¼ .28).
The one-year OS probability was 25.7% (95% CI
15.9–36.7%) vs. 15.4% (95% CI 9.0–23.3%), respectively
(p¼ .33) (Figure 2(B)).
There was no significant difference in OS based on the
type (azacitidine vs. decitabine) and schedule (5 vs. 7 vs.
10 day cycle) of HMA received, as well as disease status
(primary refractory vs. relapsed), number of treatment
lines (1 vs. 2 vs. 3 or more) or the transplant status (HSCT
received vs. not) prior to HMA therapy.
The cause of death was reported for 292 patients
(55%) of the 529 patients who died during the follow-up.
The most common cause of death was progression of dis-
ease/relapse (63.0%), whereas other causes of death
Table 1. Patient characteristics.
Patient characteristic Median or N Range or %




AML type (n¼ 650)
De novo 458 70.5
Secondary 192 29.5
Disease status (n¼ 655)
Relapsed AML 365 55.7
Primary treatment refractory AML 290 44.3









Complex karyotype (n¼ 224) 54 24.1
Monosomy karyotype (n¼ 234) 37 15.8
Chromosome 7 abnormalities (n¼ 224) 50 22.3
Chromosome 5 abnormalities (n¼ 224) 44 19.6
Number of therapy lines prior to HMA (n¼ 648) 1 1–7
alloSCT prior to initiation of HMA (months) (n¼ 618) 118 19.1
Duration of CR1 (months) prior to initiation of HMA for patients who achieved a CR1 (n¼ 322) 8.0 0.5–180
HMA agent used (n¼ 634)
Azacitidine 360 56.8
Decitabine 274 43.2
ECOG: Eastern Cooperative Oncology group; MRC: Medical Research Council; HMA: hypomethylating agent; alloSCT: allogeneic stem cell
transplant; CR1: first complete remission.
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Figure 1. Probability of overall survival from onset of HMA treatment according to MRC/LRF risk category (good/standard
vs. poor).
Figure 2: Probability of OS according to MRC/LRF risk category (good/standard vs. poor). (A) From onset of azacitidine treatment;
(B) from onset of decitabine treatment.
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included infectious complications (27.7%), cardiovascular
or pulmonary dysfunction (7.5%); however, only 1.7% of
patients died because of adverse effects directly contrib-
uted by the investigators to HMA treatment.
Our study indicates that in contrast to its use in sur-
vival prognostication with azacitidine therapy in the
frontline setting, the MRC/LRF score has limited ability to
discriminate survival with azacitidine or decitabine therapy
in the refractory and relapsed setting. This is probably
related to the generally dismal survival of these patients
and the limited clinical benefit of HMA therapy in this set-
ting. Interestingly, compared with the expanded E-ALMA
series population receiving frontline azacitidine therapy, in
our population of RR-AML patients the proportion of good
risk patients (5.4% vs. 20.9%) was higher, whereas the pro-
portion of poor risk patients (74.1% vs. 54.3%) was lower.
However, clearly the patient population in our study was
high risk given that patients either demonstrated resist-
ance to prior treatment or relapsed with a short median
CR1 time of 8 months for those who achieve a CR1; add-
itionally, 19% of patients relapsed after HSCT (Table 1).
In a recent analysis of clinical and molecular predictors
of response and OS achieved with HMA therapy in RR-
AML, we found that only patients with low proliferative
disease as indicated by peripheral blood blasts <5% and
bone marrow blast <20% at the time of HMA initiation
had improved response and OS [3]. Our study emphasizes
the extremely poor prognosis of RR-AML patients, who
are not eligible for intensive chemotherapy, and argues
for aggressive consideration of these patients for enroll-
ment in clinical trials.
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